Follow Us:

EU MDR Post Market Clinical Follow Up Studies (PMCF)

A PMCF strategy defined in a manufacturer's Post Market Surveillance (PMS) plan is critical to staying in compliance with the new Medical Devices Regulation (MDR 2017/745).

Contact us to understand how to plan a PMCF study and to find out what notified Bodies, expect from the manufacturer.

FDA 510(k) Services

Post Market Clinical Follow Up

Post Market Clinical Follow Up (PMCF) is an active collection of data on clinical experience with medical devices aftermarket release. These activities can range from an analysis of data from existing device registrations to performing a new clinical investigation. The purpose of PMCF is to confirm the clinical performance and safety of the device in real-world use and help manufacturers manage acceptable risk. Post Market Clinical Follow Up is a part of the PMS activities and is understood to be a continuous process that updates the clinical evaluation. It must be carried out following the CE marking of a device.

 

The manufacturer should collect clinical data from the use in or on the humans after it has been commercialized or put to service within its intended purpose as referred to in the relevant conformity assessment procedure. PMCF should be done with the aim of confirming the safety and performance of the device throughout its expected lifetime. It should ensure the continued acceptability of identified risks and of detecting emerging risks based on fact-based evidence.

 

The manufacturer must analyze the findings of the PMCF and record the results in the clinical evaluation report and the technical documentation. For class III and implantable devices, the clinical evaluation report must be updated at least annually.

PMCF Plan

A PMCF Plan is an important technical document that outlines a method for conducting Post-Market Clinical Follow-up on a medical device. A PMCF Plan must be submitted for regulatory approval of devices. PMCF can sometimes require you to conduct additional clinical investigations, called PMCF studies.

 

The Medical Device Regulation (EU) 2017/745 (MDR) considers the post-market clinical follow-up (PMCF) as a continuous process that updates the clinical evaluation and that shall be addressed in the manufacturer’s post-market surveillance (PMS) plan. The PMCF plan shall be part of the post-market surveillance plan.  As per MDR, a PMCF plan must include, at least:

 

  • Identify the requirements and select the device for PMCF, specific procedures, and methods
  • Provides a well-defined PMCF Plan and supports in the development (PMCF Plan Templates )
  • Review the data entered in the PMCF plan to meet the chosen objective.
  • Choose the suitable method as per the characteristics and type of medical devices.
  • Provides a well-defined PMCF study and report templates.
  • Verifies the findings and the results based on the activity chosen by the manufacturer.
  • Identify the general methods and procedures to be applied, such as the gathering of clinical experience gained, feedback from users, screening of other sources of clinical data and scientific literature;
  • Specific methods and procedures of PMCF to be applied, that is the evaluation of suitable registers or Post-market clinical studies;
  • Rationale for the appropriateness of the methods and procedures referred to in the above-mentioned points;
  • Reference to the relevant parts of the clinical evaluation report and the risk management;
  • Specific objectives to be addressed by the PMCF;
  • An assessment of the clinical data relating to equivalent or similar devices;
  • Reference to any relevant Common Specifications, harmonized standards when used by the manufacturer, and relevant guidance and
  • A comprehensive and adequately justified schedule for PMCF activities (e.g. detailed examination of data and reporting) to be undertaken by the manufacturer.

PMCF Plan Requirements

As per the EU MDR2017/745, it should be carried out to proactively collect and evaluate clinical data per the method laid out in the PMCF plan which aims at:

 

  • confirming the safety and performance throughout the expected lifetime of the device,
  • identifying previously unknown side-effects and monitoring already identified side-effects and contraindications,
  • identifying and analyzing emergent risks based on factual evidence,
  • ensuring the continued acceptability of the benefit risk ratio, and
  • identifying possible methodical misuse or off-label use of the device, with a view to proving that the intended purpose is correct.

If through PMCF, the need for preventive and/or corrective measures has been identified, the manufacturer must implement them.

 

As per MEDDEV 2.12/2 Rev 2, the clinical evaluation documentation must be actively updated with the data obtained from PMS. Where Post Market Clinical Follow Up is a part of Post Market Surveillance is not deemed necessary, this must be duly justified and documented (Exemption).

PMCF Report for Medical Devices

Annex XIV Part B of the MDR contains detailed guidelines for PMCF. The PMCF must be carried out in accordance with a documented PMCF plan, which must be presented as part of the medical device technical documentation. Findings from PMCF must be summarized on a regular basis in a PMCF Report.

 

The conclusion of post market clinical follow up report also becoming part of the device’s Clinical Evaluation Report (CER). The contents of Post Market Clinical Follow Up Record is explained in MedDev 2.12/2 rev 2 even though  it does not modified for MDR.

The important objectives of post market clinical follow up are the following

 

  • Device Adverse events
  • Severity and probability of occurrence  of Side-effects
  • Possible misuse of the device
  • Safety and performance of the device in routine use

The above generated date is summarized and recorded. The PMCF report should also contain a summary of methods  followed to collect the data. The manufacturer must justify the PMCF activities carried out is sufficient to address the objectives specified in the PMCF plan. The findings of the PMCF shall be analyzed by the manufacturer who shall document the results in a PMCF evaluation report. The PMCF evaluation report shall be part of the clinical evaluation report and the technical documentation.

Post Market Surveillance
Post Market Clinical Follow Up (PMCF)

Complete set of PMCF procedures and report templates in MS word

Clinical Evaluation Report (CER)

Documentation make easy with ready to edit and use procedures and templates

Periodic Safety Update Report (PSUR)

Complete set of procedures and record templates in MS word

PRICING

Best and economic offer from I3CGLOBAL

Post Market Surveillance
Post Market Clinical Follow Up

Frequently Asked Questions

What are the conditions when above such studies might not be required?

  1. When the medium or long-term safety and clinical performance are already known from previous use of the device;
  2. Where other appropriate post-market surveillance activities would provide sufficient data to address the risks.

What are some of the cases that justify PMCF studies?

  1. innovation, e.g., where the design of the device, the raw materials, the principles of operation, the technology, or the medical indications are novel;
  2. high-risk target populations e.g. pediatrics, elderly;
  3. high product-related risk e.g. based on design, materials, components, invasiveness, clinical procedures;
  4. identification of previously unstudied subpopulations which may show different benefit/risk-ratio e.g. hip implants in different ethnic populations and so on...

State a few examples of methodologies to carry-out PMCF studies?

  1. the extended follow-up of patients enrolled in premarket investigations;
  2. a new clinical investigation;
  3. a review of data derived from a device registry; or
  4. a review of relevant retrospective data from patients previously exposed to the device.

What is the use of the Post Market Clinical Follow Up study data?

The data and conclusions derived from the Post Market Clinical study are used to providing clinical evidence for the clinical evaluation. This may result in the need to reassess whether the device continues to comply with the General Safety and Performance Requirements (GSPR).  Such assessment may result in corrective or preventive actions, for example, changes to the instructions for use/labeling, changes to manufacturing processes, revision of the device design, or public health notifications.

Should we start the discussion?

When we undertake MDR article 61 for clinical evaluation documentation, it covers complete post market activities.